MARKET

IRWD

IRWD

Ironwood
NASDAQ
4.560
+0.110
+2.47%
After Hours: 4.600 +0.04 +0.88% 19:48 02/06 EST
OPEN
4.520
PREV CLOSE
4.450
HIGH
4.705
LOW
4.410
VOLUME
2.98M
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
0.5271
MARKET CAP
741.81M
P/E (TTM)
32.43
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IRWD last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at IRWD last week (0119-0123)?
Weekly Report · 01/26 09:59
Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications
NASDAQ · 01/26 07:11
Weekly Report: what happened at IRWD last week (0112-0116)?
Weekly Report · 01/19 10:04
Weekly Report: what happened at IRWD last week (0105-0109)?
Weekly Report · 01/12 10:03
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
NASDAQ · 01/08 14:36
Ironwood Pharmaceuticals Principal Accounting Officer Ronald Silver Reports Disposal of Common Shares
Reuters · 01/07 21:05
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating
NASDAQ · 01/07 20:25
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.